MEDELPHARM Technical Bulletin – Compaction Characterization of Piroxicam ASD Formulations

Amorphous solid dispersions (ASDs) have been widely used to improve the bioavailability of poorly water-soluble drugs. They are comprised of high molar mass polymer carriers that stabilize the APIs in their amorphous state.

However, increasing the concentration of polymer to improve the solubility of APIs can often cause poor tabletability and fail the disintegration target for immediate release. In this study, MEDELPHARM used BASF’s Kollitab™ DC 87L as a combined filler, binder, disintegrant and lubricant to improve flow, good compaction and enhanced disintegration time.

By comparing four similar formulations (with different piroxicam polyvinylpyrrolidone-Acetate/Kollitab™ ration) on the STYL’One Nano Compaction Simulator, MEDELPHARM was able to decrease disintegration time from 22 to 4 minutes, quickly, easily, and with limited amount of powder.

In this bulletin, learn how the MEDELPHARM Science Lab can conduct studies to see how different formulations will impact three critical attributes: tensile strength, disintegration time and friability at fixed compression settings.

Resources

Click on MEDELPHARM Instruments for further resources.